- Home
- EDSA vs CDIO Comparison
EDSA vs CDIO Comparison
Compare EDSA & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- CDIO
- Stock Information
- Founded
- EDSA 2015
- CDIO 2017
- Country
- EDSA Canada
- CDIO United States
- Employees
- EDSA N/A
- CDIO N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- EDSA Health Care
- CDIO Health Care
- Exchange
- EDSA Nasdaq
- CDIO Nasdaq
- Market Cap
- EDSA 6.2M
- CDIO 7.0M
- IPO Year
- EDSA N/A
- CDIO N/A
- Fundamental
- Price
- EDSA $1.83
- CDIO $4.77
- Analyst Decision
- EDSA Strong Buy
- CDIO Buy
- Analyst Count
- EDSA 1
- CDIO 1
- Target Price
- EDSA $21.00
- CDIO $60.00
- AVG Volume (30 Days)
- EDSA 35.8K
- CDIO 102.5K
- Earning Date
- EDSA 05-14-2025
- CDIO 05-15-2025
- Dividend Yield
- EDSA N/A
- CDIO N/A
- EPS Growth
- EDSA N/A
- CDIO N/A
- EPS
- EDSA N/A
- CDIO N/A
- Revenue
- EDSA N/A
- CDIO $19,902.00
- Revenue This Year
- EDSA N/A
- CDIO $1,434.82
- Revenue Next Year
- EDSA N/A
- CDIO $4,661.91
- P/E Ratio
- EDSA N/A
- CDIO N/A
- Revenue Growth
- EDSA N/A
- CDIO N/A
- 52 Week Low
- EDSA $1.55
- CDIO $3.40
- 52 Week High
- EDSA $5.59
- CDIO $53.10
- Technical
- Relative Strength Index (RSI)
- EDSA 29.28
- CDIO 39.92
- Support Level
- EDSA $1.88
- CDIO $3.88
- Resistance Level
- EDSA $2.05
- CDIO $5.20
- Average True Range (ATR)
- EDSA 0.08
- CDIO 0.48
- MACD
- EDSA -0.00
- CDIO 0.32
- Stochastic Oscillator
- EDSA 0.00
- CDIO 68.25
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.